TERAPIA DI SALVATAGGIO IN UN PAZIENTE ANZIANO AFFETTO DA SARCOMA SINOVIALE: CASE REPORT
F. Raiti, G. Buccafusca, A. Di Mari, F. Cappuccio, P. Tralongo
Vol.2 (2017), issue 3, pag. 37-44

Received 03/08/2017
Accepted for pubblication 27/09/2017
Published Sept. 2017
Review by Single-blind
jQuery UI Dialog - Animation

Soft tissue sarcomas (STSs) are a group of malignant mesenchymal tumors that originate from connective tissue. They represent 1% of adult and 7-10% of children cancers. The most common adults istotypes are undifferentiated pleomorphic sarcoma (35%), leiomyosarcoma (10%), liposarcoma (25%), and synovial sarcoma (10%). The most common type of childhood is rhabdomyosarcoma. Surgery excision with wide negative margins with or without adjuvant radiotherapy is the treatment of choice. Chemotherapy has been widely used over decades in STSs as palliative treatment in advanced cases. In the last years, the new discoveries in biological and clinical fields favored a better understanding of the disease and the introduction into clinical practice of new drugs. Today, chemotherapy can play an important role to improve survival of patients and disease free survival. We report a clinical case of an elderly patient with synovial sarcoma who shown a PFS of 20,3 months during the second line treatment with Trabectedin for 24 cycles.